Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of introducing screening for multiple myeloma and gives an update on the ongoing PROMISE study (NCT03689595), in which high-risk individuals are screened for precursor conditions to myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. Dr Ghobrial discusses how screening and earlier treatment may be key to finding a cure for myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.